​

Repare Therapeutics (RPTX) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChart

RPTX Stock Forecast

Repare Therapeutics (RPTX) stock forecast, based on 8 Wall Street analysts, predicts a 12-month average price target of $18.33, with a high of $30.00 and a low of $10.00. This represents a 1427.50% increase from the last price of $1.20.

- $6 $12 $18 $24 $30 High: $30 Avg: $18.33 Low: $10 Last Closed Price: $1.2

RPTX Stock Rating

Repare Therapeutics stock's rating consensus is Buy, based on 8 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 7 Buy (87.50%), 1 Hold (12.50%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 8 0 1 7 Strong Sell Sell Hold Buy Strong Buy

RPTX Price Target Upside V Benchmarks

TypeNameUpside
StockRepare Therapeutics1427.50%
SectorHealthcare Stocks 35.25%
IndustryBiotech Stocks 86.56%

Price Target Trends

1M3M12M
# Anlaysts--1
Avg Price Target--$10.00
Last Closing Price$1.20$1.20$1.20
Upside/Downside--733.33%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 25122--5
Mar, 25222--6
Feb, 25222--6
Jan, 25233--8
Dec, 24242--8
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 04, 2024Robert BurnsH.C. Wainwright$10.00$2.81255.87%733.33%
Feb 03, 2023Morgan Stanley$15.00$13.1414.16%1150.00%
Nov 17, 2022H.C. Wainwright$25.00$17.0047.06%1983.33%
Jun 20, 2022Joseph CatanzaroPiper Sandler$30.00$13.27126.07%2400.00%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Sep 16, 2024Piper SandlerOverweightOverweighthold
Sep 04, 2024H.C. WainwrightBuyBuyhold
Jun 09, 2023DaiwaBuyupgrade
Feb 03, 2023Morgan StanleyEqual-Weightdowngrade
Jun 20, 2022Piper SandlerOverweightOverweighthold
Jun 02, 2022Roth CapitalBuyinitialise

Financial Forecast

EPS Forecast

$-5 $-4 $-3 $-2 $-1 $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.45$-2.83$-0.69$-2.23$-2.00----
Avg Forecast$-2.00$-2.80$-0.66$-2.03$-2.14$-2.69$-2.19$-3.26$-3.54
High Forecast$-1.53$-2.14$-0.54$-1.14$-1.98$-2.08$-1.53$-2.85$-1.30
Low Forecast$-2.80$-3.91$-0.80$-2.48$-2.39$-3.30$-3.30$-3.67$-4.83
Surprise %-27.50%1.07%4.55%9.85%-6.54%----

Revenue Forecast

$0 $30M $60M $90M $120M $150M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$135.00K$7.60M$131.83M$51.13M-----
Avg Forecast$1.50M$3.99M$122.28M$59.79M$56.05M$6.71M$19.24M$9.41M$28.95M
High Forecast$1.96M$5.22M$141.57M$106.65M$62.17M$8.61M$19.24M$12.06M$37.11M
Low Forecast$1.23M$3.27M$105.44M$46.50M$53.15M$3.44M$19.24M$4.82M$14.85M
Surprise %-91.00%90.39%7.81%-14.48%-----

Net Income Forecast

$-250M $-200M $-150M $-100M $-50M $0 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-53.42M$-106.91M$-29.05M$-93.80M$-84.69M----
Avg Forecast$-84.19M$-117.67M$-27.78M$-93.80M$-84.05M$-136.71M$-126.82M$-137.24M$-148.90M
High Forecast$-64.50M$-90.15M$-22.81M$-48.08M$-83.34M$-87.55M$-64.53M$-119.98M$-54.60M
Low Forecast$-117.85M$-164.72M$-33.48M$-104.48M$-100.53M$-138.91M$-138.87M$-154.50M$-203.49M
Surprise %-36.55%-9.15%4.55%-0.76%----

RPTX Forecast FAQ

Is Repare Therapeutics stock a buy?

Repare Therapeutics stock has a consensus rating of Buy, based on 8 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 7 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Repare Therapeutics is a favorable investment for most analysts.

What is Repare Therapeutics's price target?

Repare Therapeutics's price target, set by 8 Wall Street analysts, averages $18.33 over the next 12 months. The price target range spans from $10 at the low end to $30 at the high end, suggesting a potential 1427.50% change from the previous closing price of $1.2.

How does Repare Therapeutics stock forecast compare to its benchmarks?

Repare Therapeutics's stock forecast shows a 1427.50% upside, outperforming the average forecast for the healthcare stocks sector (35.25%) and outperforming the biotech stocks industry (86.56%).

What is the breakdown of analyst ratings for Repare Therapeutics over the past three months?

  • April 2025: 20.00% Strong Buy, 40.00% Buy, 40.00% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 33.33% Strong Buy, 33.33% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 33.33% Strong Buy, 33.33% Buy, 33.33% Hold, 0% Sell, 0% Strong Sell.

What is Repare Therapeutics’s EPS forecast?

Repare Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-2.69, marking a 34.50% increase from the reported $-2 in 2024. Estimates for the following years are $-2.19 in 2026, $-3.26 in 2027, and $-3.54 in 2028.

What is Repare Therapeutics’s revenue forecast?

Repare Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $6.71M, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $19.24M, followed by $9.41M for 2027, and $28.95M for 2028.

What is Repare Therapeutics’s net income forecast?

Repare Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-137M, representing an 61.42% increase from the reported $-84.689M in 2024. Projections indicate $-127M in 2026, $-137M in 2027, and $-149M in 2028.